VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | QUAZAR AML-001: oral azacitidine as maintenance therapy in AML

Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of QUAZAR AML-001 (NCT01757535) which aimed to determine the efficacy of oral azacitidine plus best supportive care as maintenance therapy in patients with acute myeloid leukemia (AML) in complete remission. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter